FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, will exclusively distribute Spectrila® via a Managed Access Program for targeted Healthcare Providers in Russia and CIS region.
FarmaMondo to manage access to Spectrila® for patients with acute lymphoblastic leukemia in Russia, Georgia, Azerbaijan, Kyrgyzstan, Uzbekistan, Moldova.
Spectrila® has been approved in January 2016 by the EMA as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients from birth to 18 years and adults. Under this program, Medac Pharma will make Spectrila (Asparaginase, produced in E.Coli cells by recombinant DNA technology) available in collaboration with FarmaMondo in response to unsolicited requests by oncologists and other clinical specialists on an individual named-patient basis in accordance with local and international regulations
Program Contact details
For all inquiries regarding Spectrila®, please contact Spectrila MAP – Program Manager
Marco Scicolone
Tel: +41 916976371, Mscicolone@farmamondo.com
Dr. Georgy Paroshin
Tel: +7 916 020 7310, Gparoshin@farmamondo.com
About FarmaMondo
FarmaMondo is a Swiss-based pharmaceutical company with a focus on providing paid access to unlicensed medicines. Our global footprint includes commercial operations in more than 70 markets, headquartered from Switzerland with regional hubs in Europe, Asia and Latin America.
For more information about FarmaMondo please visit www.farmamondo.com.
About Medac Pharma
Medac GmbH is a Hamburg pharmaceutical company, specializing in the treatment and diagnosis of oncological, urological and autoimmune diseases since 1970, and we it is very much aware of the particular requirements of these fields. Medac takes responsibility for its actions and all its expertise is geared to the provision of qualitatively perfect and reliable products for patients, doctors, laboratory personnel and hospitals.
For more information about Medac GmbH please visit www.medac.de
